|本期目录/Table of Contents|

[1]孙煜,张晓慧,吴长刚.促红细胞生成素治疗心力衰竭15例疗效观察[J].慢性病学杂志,2014,(07):573-575.
点击复制

促红细胞生成素治疗心力衰竭15例疗效观察(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2014年07期
页码:
573-575
栏目:
专题报道
出版日期:
2014-08-31

文章信息/Info

Title:
-
作者:
孙煜 张晓慧 吴长刚
聊城市传染病医院,山东聊城252000
Author(s):
-
关键词:
心力衰竭促红细胞生成素住院时间
Keywords:
-
分类号:
R541.6
DOI:
-
摘要:
目的探讨促红细胞生成素(EPO) 治疗心力衰竭(以下简称心衰) 的疗效和对住院时间的影响。方 法将30 例心衰患者随机分为治疗组及对照组,每组15 例。对照组给予心衰的常规治疗,治疗组在常规 治疗的基础上加用EPO 治疗,比较2 组患者在治疗10 d 后的缓解率及1 年内总住院时间。结果对照组的 症状缓解率为53.3%,治疗组为80.00%,差异有统计学意义(χ2=7.28,P<0.01)。对照组1 年内平均住院 为(3.42±0.75) 次, 总住院时间(77.6±2.36) d; 治疗组1 年内平均住院(1.45±0.47) 次, 总住院时间 (30.5±2.12) d,差异均有统计学意义(t 分别为1.761 和1.782,P 均<0.01)。结论EPO 用于心衰治疗, 可减少患者的住院时间,提高症状缓解率,值得临床推广应用。
Abstract:
-

参考文献/References:

[1] Felker GM, Shaw LK, Stough WG, et al. Anemia in patients with heart failure and preserved systolic function [J]. Am Heart J, 2006,151(2):457-462.
[2] Ezekowitz J, McAlister FA, Humphries KH, et al. The asso? ciation among renal insufficiency, pharmacotherapy, and out? comes in 6,427 patients with heart failure and coronary artery disease [J]. J Am Coll Cardiol, 2004,44(8):1587-1592.
[3] Iversen PO, Woldbaek PR, T?nnessen T, et al. Decreased he? matopoiesis in bone marrow of mice with congestive heart fail? ure [J]. Am J Physiol Regul Integr Comp Physiol, 2002,282 (1):R166-R172.
[4] Ogino A, Takemura G, Kawasaki M, et al. Erythropoietin re? ceptor signaling mitigates renal dysfunction- associated heart failure by mechanisms unrelated to relief of anemia [J].J Am Coll Cardiol, 2010,56(23):1949-1958.
[5] Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult [J]. J Am Coll Cardiol, 2005,46(6):e1-82.
[6] 陆再英,钟南山.内科学[M]. 7 版.北京:人民卫生出版社, 2007:467.
[7] 中华医学会.临床诊疗指南:心血管分册[M].北京:人民卫生出 版社,2009.
[8] American Heart Association. Heart Disease and stroke statis? tics: 2005 Update [M].Dallas, Tex: American Heart Associ? ation, 2005.
[9] Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in func? tional capacity and a significant increase in mortality in patients with advanced heart failure [J].J Am Coll Cardiol, 2002,39 (11):1780-1786.
[10] Silverberg DS, Wexler D, Blum M, et al. The use of subcuta? neous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure im ? proves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations [J]. J Am Coll Cardi? ol, 2000,35(7):1737-1744.
[11] Silverberg DS, Wexler D, Sheps D, et al. The effect of correc? tion mild anemia in severe resistant congestive heart failure us? ing subcutaneous erythropoietin and intravenous iron: a ran? domized controlled study [J]. J Am Coll Cardiol, 2001,37 (7):1775-1780.

备注/Memo

备注/Memo:
作者简介:孙煜,大学本科,主治医师,从事呼吸道常见 疾病的临床诊治工作 通信作者:孙煜,E-mail: sunyu0409@yeah.ne
更新日期/Last Update: 2014-08-30